Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
AstraZeneca
Dow
Mallinckrodt
Express Scripts

Last Updated: August 13, 2022

Investigational Drug Information for Sirna-027


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for Sirna-027?

Sirna-027 is an investigational drug.

There have been 28 clinical trials for Sirna-027. The most recent clinical trial was a Phase 2 trial, which was initiated on January 1st 2016.

The most common disease conditions in clinical trials are Pancreatic Neoplasms, Adenocarcinoma, and Macular Degeneration. The leading clinical trial sponsors are Nitto Denko Corporation, National Cancer Institute (NCI), and Allergan.

There are three US patents protecting this investigational drug and two hundred and fifty-eight international patents.

Recent Clinical Trials for Sirna-027
TitleSponsorPhase
Tarlox and Sotorasib in Patients With KRAS G12C MutationsRain Therapeutics Inc.Phase 1/Phase 2
Tarlox and Sotorasib in Patients With KRAS G12C MutationsMedical University of South CarolinaPhase 1/Phase 2
Evaluation of Safety & Efficacy of MIR 19 ® Inhalation Solution in Patients With Moderate COVID-19St. Petersburg Research Institute of Vaccines and SeraPhase 2

See all Sirna-027 clinical trials

Clinical Trial Summary for Sirna-027

Top disease conditions for Sirna-027
Top clinical trial sponsors for Sirna-027

See all Sirna-027 clinical trials

US Patents for Sirna-027

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Sirna-027 See Plans and Pricing Recombinant vectors Tocagen Inc. (San Diego, CA) See Plans and Pricing
Sirna-027 See Plans and Pricing Compositions and methods to control angiogenesis with cupredoxins The Board of Trustees of the University of Illinois (Urbana, IL) See Plans and Pricing
Sirna-027 See Plans and Pricing Recombinant vectors Tocagen Inc. (San Diego, CA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Sirna-027

Drugname Country Document Number Estimated Expiration Related US Patent
Sirna-027 Australia AU2009303690 2028-09-26 See Plans and Pricing
Sirna-027 Brazil BRPI0919113 2028-09-26 See Plans and Pricing
Sirna-027 Canada CA2738472 2028-09-26 See Plans and Pricing
Sirna-027 China CN102227501 2028-09-26 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
AstraZeneca
Dow
Mallinckrodt
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.